Psychedelic medicalization, public discourse, and the morality of ego dissolution

Introduction

Psychedelic substances, long embedded in diverse shamanic and religious practices, are being repositioned in recent years as medicines by a constellation of scientific researchers, regulators, media institutions, and patient groups. Recent clinical research in the United States and the United Kingdom, aided by modern brain imaging and psychometrics, reports promising results for conditions such as treatment-resistant depression, addictions, and end-of-life distress; unlike daily psychiatric medications, many psychedelic-assisted therapies involve one or two carefully managed dosing sessions intended to catalyse lasting psychological change. In these clinical contexts, experiences described as mystical or involving "ego dissolution" have been correlated with better outcomes, and trial settings increasingly scaffold the phenomenology of sessions with ritualised décor, music, and therapeutic preparation. This article sets out to examine how scientific research into psychedelic medicine is represented in popular media and how those representations translate scientific objectivity into moral and political claims. Gearin and colleagues conduct a critical discourse analysis of recent popular-media coverage in the US and UK to show how public communication of psychedelic science often naturalises particular moral orientations—notably neoliberal individualism and specific anti-authoritarian framings—as pharmacological and healthy, and to trace the ways psychedelic ego-dissolution discourse has become entangled with commercial and regulatory projects that shape emerging practices of medicalisation.